COVID-19 vaccine immunogenicity in people with HIV

Thumbnail image

Download files

DOI

https://doi.org/10.1097/QAD.0000000000003429

Language of the publication
English
Date
2023-01-01
Type
Article
Author(s)
  • Costiniuk, Cecilia T.
  • Galipeau, Yannick
  • Harris, Marianne
  • Hull, Mark
  • Brumme, Zabrina L.
  • Lapointe, Hope R.
  • Brockman, Mark A.
  • Margolese, Shari
  • Mandarino, Enrico
  • Samarani, Suzanne
  • Vulesevic, Branka
  • Lebouché, Bertrand
  • Angel, Jonathan B.
  • Routy, Jean-Pierre
  • Cooper, Curtis L.
  • Anis, Aslam H.
  • Lee, Terry
  • Kovacs, Colin
  • Jenabian, Mohammad-Ali
  • Chambers, Catharine
  • Brockman, Mark A.
  • Samji, Hasina
  • Burchell, Ann N.
  • Ostrowski, Mario
  • Tan, Darrell H. S.
  • Walmsley, Sharon
  • Singer, Joel
  • Hull, Mark
  • Brumme, Zabrina L.
  • Lapointe, Hope R.
Publisher
Wolters Kluwer Health, Inc.

Abstract

OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals. DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses. METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups. RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response. CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.

Subject

  • Health

Keywords

  • AIDS Vaccines*,
  • Antibodies,
  • COVID-19 Vaccines,
  • COVID-19* / prevention & control,
  • Canada,
  • HIV Infections*,
  • Humans,
  • Immunogenicity, Vaccine,
  • Prospective Studies,
  • RNA, Viral,
  • SARS-CoV-2

Rights

Pagination

F1-F10

Peer review

Yes

Open access level

Gold

Identifiers

PubMed ID
36476452
ISSN
1473-5571

Article

Journal title
AIDS
Journal volume
37
Journal issue
1

Sponsors

Supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075), and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by the National Research Council of Canada (NRC)'s Pandemic Response Challenge Program.

Download(s)

URI

Collection(s)

Communicable diseases

Full item page

Full item page

Page details

Date modified: